Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome

LEUKEMIA: (2003) 17, 463-465. doi:10.1038/sj.leu.2402814

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2003-02, Vol.17 (2), p.463-465
Hauptverfasser:	Drummond, M W, Lush, C J, Vickers, M A, Reid, F M, Kaeda, J, Holyoake, T L
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Bone Marrow Cells - pathology Cancer Research Chemotherapy Critical Care Medicine Diagnosis Drug therapy Female Fusion Proteins, bcr-abl - genetics Gene Expression Regulation, Neoplastic Granulocytes - pathology Granulocytes - physiology Hematology Humans Imatinib Imatinib Mesylate Intensive Internal Medicine Medical sciences Medicine Medicine & Public Health Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - genetics Oncogenes Oncology Patient outcomes Pharmacology. Drug treatments Philadelphia Chromosome Piperazines - therapeutic use Pyrimidines - therapeutic use Remission Risk factors RNA, Messenger - genetics spotlight-correspondence Transcription, Genetic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!